MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate many intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Major trial goals had been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people, though one of many exploratory https://bda36610987.blog2learn.com/78748750/top-m3541-secrets